Sponsor:
Revolution Medicines, Inc.
Code:
NCT06881784
Conditions
NSCLC (Non-small Cell Lung Cancer)
Non-Small Cell Lung Cancer
NSCLC
NSCLC (Non-small Cell Lung Carcinoma)
NSCLC (Advanced Non-small Cell Lung Cancer)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
daraxonrasib
docetaxel
Brief summary:
Conditions
NSCLC (Non-small Cell Lung Cancer)
Non-Small Cell Lung Cancer
NSCLC
NSCLC (Non-small Cell Lung Carcinoma)
NSCLC (Advanced Non-small Cell Lung Cancer)
Study ID
NCT06881784
Start date
May 6, 2025
Status verified date
Jul, 2026
Completion date
Dec 1, 2030
Anticipated
Primary completion date
Dec 1, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
590 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: daraxonrasib
active comparator: docetaxel
Interventions
daraxonrasib
docetaxel
Primary outcome measure
Central contacts
Locations
UC Irvine Health
Recruiting
Orange, California, United States, 92868
Sponsor
Revolution Medicines, Inc.
Last update posted
Nov 6, 2026
Last verified
Jul, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Revolution Medicines, Inc. on 2026-11-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.